111 related articles for article (PubMed ID: 30036610)
1. mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.
Chiang CT; Demetriou AN; Ung N; Choudhury N; Ghaffarian K; Ruderman DL; Mumenthaler SM
Cancer Lett; 2018 Oct; 434():152-159. PubMed ID: 30036610
[TBL] [Abstract][Full Text] [Related]
2. Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells.
Amri J; Molaee N; Karami H
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3361-3367. PubMed ID: 31759360
[TBL] [Abstract][Full Text] [Related]
3. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
Amri J; Molaee N; Baazm M; Karami H
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2781-2787. PubMed ID: 31554377
[TBL] [Abstract][Full Text] [Related]
4. Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Saafan H; Alahdab A; Michelet R; Gohlke L; Ziemann J; Holdenrieder S; McLaughlin KM; Wass MN; Cinatl J; Michaelis M; Kloft C; Ritter CA
Cells; 2021 Mar; 10(4):. PubMed ID: 33804833
[TBL] [Abstract][Full Text] [Related]
5. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Gohlke L; Alahdab A; Oberhofer A; Worf K; Holdenrieder S; Michaelis M; Cinatl J; Ritter CA
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834189
[TBL] [Abstract][Full Text] [Related]
6. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.
Safaric Tepes P; Pal D; Lindsted T; Ibarra I; Lujambio A; Jimenez Sabinina V; Senturk S; Miller M; Korimerla N; Huang J; Glassman L; Lee P; Zeltsman D; Hyman K; Esposito M; Hannon GJ; Sordella R
Elife; 2021 Jul; 10():. PubMed ID: 34254585
[TBL] [Abstract][Full Text] [Related]
7. Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer.
Pal AS; Bains M; Agredo A; Kasinski AL
Biochem Pharmacol; 2021 Jul; 189():114154. PubMed ID: 32681833
[TBL] [Abstract][Full Text] [Related]
8.
McMahon NP; Solanki A; Wang LG; Montaño AR; Jones JA; Samkoe KS; Tichauer KM; Gibbs SL
Theranostics; 2024; 14(7):2816-2834. PubMed ID: 38773974
[No Abstract] [Full Text] [Related]
9. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Zhang G; Fang B; Liu RZ; Lin H; Kinose F; Bai Y; Oguz U; Remily-Wood ER; Li J; Altiok S; Eschrich S; Koomen J; Haura EB
J Proteome Res; 2011 Jan; 10(1):305-19. PubMed ID: 21080693
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.
Praveen P; Hülsmann H; Sültmann H; Kuner R; Fröhlich H
Sci Rep; 2016 Jun; 6():27514. PubMed ID: 27279498
[TBL] [Abstract][Full Text] [Related]
11. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
[TBL] [Abstract][Full Text] [Related]
12. Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu Y; Gao W; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 May; 46(5):545-551. PubMed ID: 34148892
[TBL] [Abstract][Full Text] [Related]
13. BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.
Li F; Yu J; Pan T; Feng H; Li J; Yu B; Fan Z; Sang Q; Chen M; Zang M; Hou J; Wu X; Yu Y; Li YY; Yan C; Zhu Z; Su L; Liu B
Adv Sci (Weinh); 2023 Dec; 10(34):e2303091. PubMed ID: 37863665
[TBL] [Abstract][Full Text] [Related]
14. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Li J; Bennett K; Stukalov A; Fang B; Zhang G; Yoshida T; Okamoto I; Kim JY; Song L; Bai Y; Qian X; Rawal B; Schell M; Grebien F; Winter G; Rix U; Eschrich S; Colinge J; Koomen J; Superti-Furga G; Haura EB
Mol Syst Biol; 2013 Nov; 9():705. PubMed ID: 24189400
[TBL] [Abstract][Full Text] [Related]
15. Root Extract of
Park HJ; Park SH
Nutr Cancer; 2023; 75(10):1945-1957. PubMed ID: 37870977
[TBL] [Abstract][Full Text] [Related]
16. Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer.
Ye M; Wang S; Wan T; Jiang R; Qiu Y; Pei L; Pang N; Huang Y; Huang Y; Zhang Z; Yang L
J Cancer; 2017; 8(18):3774-3784. PubMed ID: 29151965
[TBL] [Abstract][Full Text] [Related]
17. Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy.
Wang H; Lai Y; Li D; Karges J; Zhang P; Huang H
J Med Chem; 2024 Jan; 67(2):1336-1346. PubMed ID: 38183413
[TBL] [Abstract][Full Text] [Related]
18. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.
Werner AN; Kumar AI; Charest PG
Mol Biol Cell; 2023 Dec; 34(13):ar128. PubMed ID: 37729017
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer.
Rashid NS; Boyd DC; Olex AL; Grible JM; Duong AK; Alzubi MA; Altman JE; Leftwich TJ; Valentine AD; Hairr NS; Zboril EK; Smith TM; Pfefferle AD; Dozmorov MG; Harrell JC
Sci Rep; 2022 Dec; 12(1):21248. PubMed ID: 36482068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
